Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Immunol Commun1
Search Results
Sort by
- Bookeditors, Frank Porecca, Tamara King.Contents:
Analgesics for cancer pain / Tamara King & Frank Porreca
Cancer pain assessment and consensus guidelines / Brian Wilhelmi & Paul J. Christo
Role of step 2 opioid analgesics in mild-to-moderate pain intensity treatment / Wojciech Leppert
Opioid analgesics for severe cancer pain / Phillip Good & Janet Hardy
Alternative opioids and administration routes / Mellar P. Davis
Adjuvant analgesics for cancer pain / Russell K. Portenoy & Ebtesam Ahmed
Analgesics for breakthrough pain / Sebastiano Mercadante
Emerging analgesics and future directions : targeting bone remodeling / Flaminia Coluzzi
Emerging analgesics and future directions : targeting neuroplasticity / Alysia N. Lozano-Ondoua & Todd W. Vanderah
Index. - ArticleLee CJ, Robbins JB.Immunol Commun. 1978;7(5):503-18.Studies were conducted on the characterization of Haemophilus influenzae type b polysaccharide (HITB-PS) and its mitogenic activity upon peripheral lymphocytes. This capsular polysaccharide was found to contain hexosamines and hexoses in addition to the main components of ribose and ribitol phosphate. The molecular weight of HITB-PS was determined as 585,000. The affinity constant of HITB-PS to unfractionated lymphocytes was 3.13 X 10(3) M-1 with 1.11 X 10(4) binding sites per cell. HITB-PS was found to be mitogenic for both human T and B lymphocytes. At optimum doses, a three to five fold increase in 3H-thymidine incorporation into T and B cells was observed. Higher than optimum doses resulted in suppression of this mitogenicity. The effect of concanavalin A (Con A) mitogenicity was detected in T and B cells treated with effective as well as suppressive doses of HITB-PS; the mitogenic activities of Con A and HITB-PS were found to be independent of each other.